International Federation for Surgery of Obesity and Metabolic Disorders, Rione Sirignano, 5, 80121, Naples, Italy.
Obes Surg. 2021 Jan;31(1):3-25. doi: 10.1007/s11695-020-05134-7. Epub 2021 Jan 6.
PreambleThe International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) has played an integral role in educating both the metabolic surgical and the medical communities at large about the role of innovative and new surgical and or endoscopic interventions in treating adiposity-based chronic diseases. The single anastomosis duodenal-ileal bypass with sleeve gastrectomy/one anastomosis duodenal switch (SADI-S/OADS) is a relatively new procedure that has been proposed as an alternative to the conventional duodenal switch (DS) procedure. The IFSO published a position paper on SADI-S/OADS in 2018 with which concluded that this procedure was likely to be a safe and efficacious treatment for adiposity and its related diseases. However, it noted that there was insufficient long-term data and minimal high-level evidence available. The position statement called for patients to be enrolled in long-term multidisciplinary care encouraged the registration of patients in national registries, and called for more randomized controlled trials (RCT) (Obes Surg 28:1207-16, 2018) involving the procedure. The following position statement is an update of the previous position statement. It is issued by the IFSO SADI-S/OADS task force and has been reviewed and approved by both the IFSO Scientific Committee and Executive Board. This statement is based on current clinical knowledge, expert opinion, and published peer-reviewed scientific evidence. It will be reviewed again in 2 years.
前言国际肥胖与代谢外科学会（IFSO）在教育代谢外科医生和广大医疗社区方面发挥了重要作用，使他们了解创新的新手术和/或内镜干预在治疗肥胖相关慢性疾病方面的作用。单吻合口十二指肠空肠旁路术联合袖状胃切除术/十二指肠转位术（SADI-S/OADS）是一种相对较新的手术，它被提议作为传统十二指肠转位术（DS）的替代方法。IFSO 于 2018 年发布了一份关于 SADI-S/OADS 的立场文件，该文件得出的结论是，该手术可能是一种安全有效的肥胖症及其相关疾病的治疗方法。然而，该文件指出，长期数据不足，高级别证据有限。该立场声明呼吁患者接受长期多学科护理，并鼓励将患者登记到国家登记处，同时呼吁开展更多涉及该手术的随机对照试验（RCT）（Obes Surg 28:1207-16, 2018）。本立场声明是对上一份声明的更新。它由 IFSO SADI-S/OADS 工作组发布，并已由 IFSO 科学委员会和执行委员会审查和批准。本声明基于当前的临床知识、专家意见和已发表的同行评议的科学证据。它将在两年内再次审查。
